idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Medienpartner:
Wissenschaftsjahr


Share on: 
08/09/2018 16:12

Possible treatment for Charcot-Marie-Tooth disease (CMT1A) discovered

Stefan Weller Stabsstelle Unternehmenskommunikation, Presse- und Öffentlichkeitsarbeit
Universitätsmedizin Göttingen - Georg-August-Universität

    The dietary supplement Lecithin improves the myelination of diseased Schwann cells. Publication in Nature Communications

    (mpi/umg) Charcot-Marie-Tooth (CMT) disease is the most common hereditary neuropathy and affects more than two million people worldwide. Alone in Germany, at least 30.000 people suffer from Charcot-Marie-Tooth neuropathy which belongs to the class of rare disease. In a close collaboration at the Göttingen campus, researchers at the Max-Planck-Institute for Experimental Medicine and the University Medical Center of Göttingen now hope to use lecithin, a harmless dietary supplement to treat the incurable illness. The results of the study were published in „Nature Communications“.

    Due to a genetic defect that causes a duplication of the PMP22 gene, patients with a Charcot-Marie-Tooth disease develop a slowly progressive impairment of their peripheral nerves (CMT1A). Early symptoms, like walking difficulties or deformed feet can already occur during childhood. Later, muscle muscle weekness in legs and arms occur, but also numbness, prickling or pain. In rare cases, patients may be forced to use wheelchairs.

    The axons, projections of nerve cells in the peripheral nervous system, are surrounded by supporting cells over their entire length. These Schwann cells produce a fatty layer, the myelin, around the axons which allows for a faster transfer of electric signals. Using a transgenic rat model of CMT1A, scientists at the Max-Planck-Institute for Experimental Medicine and the University Medical Center in Göttingen, as well as neuroscientists from Leipzig, Würzburg, Heidelberg and Aachen now discovered that diseased Schwann cells show a decreased fat metabolism during their development which causes the impaired myelination. “The production of myelin is extremely laborious for Schwann cells. A disruption, like the one the Charcot-Marie-Tooth disease causes, leaves the nerve fibers without myelin, which limits their functionality”, explains the first author of the study, Robert Fledrich, Max-Planck-Institute of Experimental Medicine and Institute of Anatomy of Leipzig University Medicine.

    Schwann cells use Phospholipids for the myelination
    Using lecithin, the reduced fat production of Schwann cells may be circumvented and the disturbed myelination in Charcot-Marie-Tooth disease thus be improved. Lecithin is produced from soy or yolk and consists of phospholipids. It is a harmless dietary supplement and the main ingredient of myelin. Initially, the scientists were able to show that the phospholipids in genetically modified rats were absorbed by the Schwann cells and used for the production of myelin.

    Therapy studies with diseased rats that were given lecithin in various doses not only showed that a treatment with phospholipids promotes the myelination. “It significantly eases the course of the disease regardless of the start of the therapy”, explains Ruth Stassart, a neuropathologist from the Departement of Neuropathology of Leipzig University Medicine and Max-Planck Institute for Experi-mental Medicine, who co-lead the study. “The promising data from the animal testing and especially the already proven compatibility of with humans, promote Lecithin as a therapeutic agent for the Charcot-Marie-Tooth disease as well as possibly for similar demyelinating diseases”, adds Michael Sereda, a neurologist at the Department of Clinical Neurophysiology at the University Medical Center Göt-tingen and group leader at the Max-Planck-Institute for Experimental Medicine who co-directed the study together with Ruth Stassart.

    The participating neurologists and neuroscientists now plan to use these findings from animal models in order to help patients by initiating clinical trials.

    Original publication:
    "Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy", R. Fledrich, T. Abdelaal, L. Rasch, V. Bansal, V. Schütza, B. Brügger, C. Lüchtenborg, T. Prukop, J. Stenzel, R.U. Rahman, D. Hermes, D. E-wers, W. Möbius, T. Ruhwedel, I. Katona, J. Weis, D. Klein, R. Martini, W. Brück, W.C. Müller, S. Bonn, I. Bechmann, K.A. Nave, R.M. Stassart & M.W. Sereda; Na-ture Communications; 2. August 2018 (DOI: 10.1038/s41467-018-05420-0)

    On www.CMT-NET.de patients, scientists and doctors are informed on the research relating to CMT in Germany.


    contact for scientific information:

    Prof. Dr. med. Michael W. Sereda
    Max-Planck-Institute of Experimental Medicine
    Research Group “Molecular and Translational Neurology”
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    University Medical Center Göttingen – University of Göttingen
    Department of Clinical Neurophysiology
    Robert-Koch-Str. 40, 37075 Göttingen

    Phone: +49-551-3899-760/732 oder +49-551-39-9662
    Email: sereda@em.mpg.de
    www.cmt-net.de, www.neurologie.uni-goettingen.de, www.em.mpg.de

    Dr. rer. nat. Robert Fledrich
    Institute of Anatomy – Leipzig University Medicine
    Liebigstr, 13, 04103 Leipzig

    Max-Planck-Institute of Experimental Medicine
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    Phone: +49-341-9715037
    Email: fledrich@em.mpg.de

    Dr. med. Ruth M. Stassart
    Max-Planck-Institute of Experimental Medicine
    Research Group “Remyelination and Nerve Repair”
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    Abteilung für Neuropathologie, Department für Diagnostik
    Leipzig University Medicine
    Liebigstr. 26, 04103 Leipzig

    Phone:+49-341-9715090
    Email: stassart@em.mpg.de

    Prof. Klaus-Armin Nave, PhD
    Max-Planck-Institute of Experimental Medicine
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    Email: nave@em.mpg.de
    Phone: +49-551-3899-760


    original publication:

    "Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy", R. Fledrich, T. Abdelaal, L. Rasch, V. Bansal, V. Schütza, B. Brügger, C. Lüchtenborg, T. Prukop, J. Stenzel, R.U. Rahman, D. Hermes, D. E-wers, W. Möbius, T. Ruhwedel, I. Katona, J. Weis, D. Klein, R. Martini, W. Brück, W.C. Müller, S. Bonn, I. Bechmann, K.A. Nave, R.M. Stassart & M.W. Sereda; Nature Communications; 2. August 2018 (DOI: 10.1038/s41467-018-05420-0)


    Criteria of this press release:
    Journalists
    Biology, Medicine
    transregional, national
    Research projects, Research results
    English


    Compared to healthy rats (left), rats with the Charcot-Marie-Tooth disease (central) show less myelin surrounding the axons, visible as the missing blue rings.


    For download

    x

    Prof. Dr. Michael W. Sereda, Department of Clinical Neurophysiology at the University Medical Center Göttin-gen, Max-Planck-Institute for Experimental Medicine


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).

    Cookies optimize the use of our services. By surfing on idw-online.de you agree to the use of cookies. Data Confidentiality Statement
    Okay